Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Summary

Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of IMX-110 in combination with Tislelizumab. The recommended Phase 2 dose (RP2D) will be evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1 protocol during the conduct of the Phase 1 study.

Timeline

Start

2023-02-03

Primary completion

2024-01-24

Completion

2024-01-24

Drugs

Indications